Quince Therapeutics (NASDAQ:QNCX) Receives "Buy" Rating from D. Boral Capital

Key Points

• D. Boral Capital has reiterated a "buy" rating for Quince Therapeutics, setting a price target of $4.00, indicating a potential upside of 138.10% from the current stock price.
• Multiple research firms recently provided varied ratings, with QNCX receiving a consensus rating of "Buy" and an average price target of $8.14.
• Quince Therapeutics reported a quarterly loss of ($0.34) earnings per share, which fell short of analysts' expectations of ($0.28).

Quince Therapeutics (NASDAQ:QNCX - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at D. Boral Capital in a report issued on Friday,Benzinga reports. They currently have a $4.00 price objective on the stock. D. Boral Capital's price target points to a potential upside of 138.10% from the company's current price.

Several other research firms have also recently issued reports on QNCX. JMP Securities lowered their price objective on shares of Quince Therapeutics from $9.00 to $8.00 and set a "market outperform" rating for the company in a research report on Tuesday. Citigroup started coverage on shares of Quince Therapeutics in a research report on Tuesday, August 5th. They issued an "outperform" rating for the company. Wall Street Zen cut shares of Quince Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, Citizens Jmp started coverage on shares of Quince Therapeutics in a research report on Tuesday, August 5th. They issued a "strong-buy" rating and a $9.00 price target for the company. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $8.14.

Quince Therapeutics Price Performance

Quince Therapeutics stock opened at $1.68 on Friday. The stock has a market cap of $90.23 million, a price-to-earnings ratio of -1.54 and a beta of 1.02. The company has a debt-to-equity ratio of 1.45, a current ratio of 5.00 and a quick ratio of 4.05. Quince Therapeutics has a 1 year low of $0.51 and a 1 year high of $2.45. The firm has a 50-day moving average of $1.60 and a two-hundred day moving average of $1.37.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). On average, research analysts forecast that Quince Therapeutics will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Quince Therapeutics

Several hedge funds have recently modified their holdings of QNCX. Bridgeway Capital Management LLC lifted its position in Quince Therapeutics by 20.9% during the second quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company's stock valued at $212,000 after acquiring an additional 22,200 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in Quince Therapeutics during the second quarter valued at approximately $4,172,000. XTX Topco Ltd purchased a new stake in Quince Therapeutics during the second quarter valued at approximately $37,000. Rockefeller Capital Management L.P. purchased a new stake in Quince Therapeutics during the second quarter valued at approximately $280,000. Finally, Ieq Capital LLC purchased a new stake in Quince Therapeutics during the first quarter valued at approximately $1,073,000. Hedge funds and other institutional investors own 30.75% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.